Please login to the form below

Not currently logged in
Email:
Password:

daratumumab

This page shows the latest daratumumab news and features for those working in and with pharma, biotech and healthcare.

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

measure. The UK’s health technology assessment agency rejected Darzalex (daratumumab) as a third-line treatment for patients with multiple myeloma last March, to the consternation of the company and patients ... Daratumumab is an exciting and

Latest news

  • J&J files would-be prostate cancer blockbuster in US J&J files would-be prostate cancer blockbuster in US

    That view was echoed by Jefferies Jeffrey Holford, who says J&J’s so-called TIRADE products - Tremfya (guselkumab) for psoriasis, cancer drug Imbruvica (ibrutinib), anticoagulant rivaroxaban (Xarelto), apalutamide, Darzalex (daratumumab)

  • SMC backtracks on Janssen’s multiple myeloma treatment Darzalex SMC backtracks on Janssen’s multiple myeloma treatment Darzalex

    Jennifer Lee, director of HEMAR and advocacy at Janssen, said: “Janssen welcomes the SMC’s positive recommendation for daratumumab as a monotherapy for relapsed or refractory multiple myeloma.”. ... other therapies means that there is a real and

  • Biosimilars eat into J&J's Remicade sales Biosimilars eat into J&J's Remicade sales

    multiple myeloma therapy Darzalex (daratumumab) almost tripling to $299m compared to a year ago, thanks to expanded indications including second-line use.

  • Redefining launch excellence in 2017 Redefining launch excellence in 2017

    For example, Janssen’s Darzalex (daratumumab) was granted accelerated approval based on response rates for patients with multiple myeloma who have received at least three prior lines of therapy.

  • Amgen's Kyprolis tops Velcade in myeloma trial Amgen's Kyprolis tops Velcade in myeloma trial

    Multiple myeloma is becoming increasingly competitive, however, thanks to new launches such as Bristol-Myers Squibb's Empliciti (elotuzumab), Novartis' Farydak (panobinostat) and Johnson &Johnson's Darzalex (daratumumab).

More from news
Approximately 9 fully matching, plus 25 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Marketing strategy in complex environments

    Marketing strategy in complex environments. Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through

  • ASCO 2015: What you missed in Chicago

    In particular, daratumumab in double refractory multiple myeloma represents a truly transformational treatment in this area for patients who have tried all current options[4]. ... In an area dominated by combination trials, daratumumab showed significant

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics